Recent Updates
Recently added Catalysts

Tick-borne encephalitis vaccine

Phase 2

Tick-borne Encephalitis | Monoclonal antibody | Other |Pfizer, Inc.|Last Updated: May 21, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials2
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00161772Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.PHASE2 COMPLETED -Mar 1, 2002Aug 1, 2002May 21, 201523 Austria, Germany
NCT00161798Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.PHASE2 COMPLETED -Sep 1, 2001Mar 1, 2002May 21, 201523 Germany
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Interventions
NameTypeDescription
Tick-borne Encephalitis VaccineBIOLOGICAL -
Unlock Study Design Details
Eligibility Criteria
Age Range1 Year — 5 Years
SexALL
Healthy VolunteersYes
Study Sites23

Inclusion Criteria: Male and female children will be eligible for participation in this study if: * they are 1 year (from the 1st birthday) to 6 years (to the last day before the 6th birthday) old; * they are clinically healthy; * their legal representative understands the nature of the study, agr...

Countries:AustriaGermany
Unlock Eligibility Criteria